Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Headquarters in Amsterdam
Retrieved on:
Wednesday, November 23, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Lighting, Head, Marketing, WAAW, HIV, Government, Senior, Excellency, Credit, Netherlands Foreign Investment Agency, Multimedia, Commerce, Interview, Science, Medicine, European Medicines Agency, CNS, Ambassador, Pain, Neurological disorder, Growth, Corporation, Health, Trade Register, Patient, Management, Pharmaceutical industry, Shionogi
SHIONOGI B.V., the European subsidiary of SHIONOGI & Co., Ltd. (Head Office: Osaka, Japan; hereafter "Shionogi"), officially opened the doors to its new European Headquarters in Herengracht, Amsterdam, today, marking the next stage of growth for the Japanese pharmaceutical company.
Key Points:
- SHIONOGI B.V., the European subsidiary of SHIONOGI & Co., Ltd. (Head Office: Osaka, Japan; hereafter "Shionogi"), officially opened the doors to its new European Headquarters in Herengracht, Amsterdam, today, marking the next stage of growth for the Japanese pharmaceutical company.
- European CEO, Huw Tippett said: The decision to open our new headquarters in Amsterdam was an easy one for the business.
- Amsterdam is a great city with a thriving life science community across both biopharmaceuticals and medical technology.
- The new office adds further strength to Shionogis European capabilities, as we continue on our ambitious growth journey.